SuperworthGreenland Mines GRML
- Market cap
- $18.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Greenland Mines' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $238.7K | $271.1K | $124.3K | $321.3K | $400.5K+68% |
| SG&A | $6K−96% | $4K−98% | $9.2K−97% | $2.3K−85% | $52.2K+774% | $66K+1537% | $850.3K+9144% | $729.6K+31065% | $231.4K+344% | $585.4K+787% | $6.2M+631% | $577.9K−21% |
| −$123.7K−31% | −$110.7K−54% | −$672K+106% | −$395.6K+62% | −$2.9M+2220% | −$1.9M+1572% | −$1.6M+136% | −$1.9M+379% | −$1.9M−35% | −$1.8M−2% | −$9.5M+499% | −$5.5M+190% | |
| Interest expense | $20.4K | $15.7K | n/a | $15.1K−25% | $45K+121% | $296.6K+1784% | $553.9K | $1.8M+11584% | $1.2M+2520% | −$1.2M | $1.6K−100% | $4.9K−100% |
| Pre-tax income | −$144.1K | −$126.5K | −$672K | −$451.6K+71% | −$3M+1954% | −$2.1M+1535% | −$2.1M+215% | −$4.1M+806% | −$2.9M−2% | −$1.3M−36% | −$13.9M+555% | −$3.7M−10% |
| $148.9K+87% | $112K−54% | $49.1K−81% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$144.1K | −$126.5K | −$672K | −$451.6K+71% | −$3M+1954% | −$2.1M+1535% | −$2.1M+215% | −$4.1M+806% | −$2.9M−2% | −$1.3M−36% | −$13.9M+555% | −$3.7M−10% |
| −$0.50 | −$0.50 | −$2.00 | −$1.50 | −$9.00+1700% | −$4.00+700% | −$4.00+100% | −$6.00+300% | −$2.50−72% | −$1.00−75% | −$7.50+88% | −$1.50−75% | |
| 302.6K | 302.6K | 302.6K | 313.6K | 333.8K+10% | 543.3K+80% | 550.5K+82% | 679K+117% | 1.2M+256% | 1.4M+167% | 1.9M+241% | 2.5M+273% |
EPS, diluted: 5 periods, Q1 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY23 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q2 FY24: a loss quarter: its basic count, printed 3 months.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Greenland Mines' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GRMLGreenland Mines | $18.4M | n/m | n/a | n/m | n/m | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $64.6M | 13.6× | 14.8× | 1.1× | +6% | 4.9% |
More on Greenland Mines
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .